EME and JCR Pharma have signed a joint research and development agreement aimed at drug discovery utilizing next-generation antibodies VHH.

Epsilon Molecular Engineering Co., Ltd. (Headquarters: Saitama City, Saitama Prefecture, President: Naoto Nemoto, hereinafter referred to as EME) has entered into a joint research and development agreement with JCR Pharmaceuticals Co., Ltd. (Headquarters: Ashiya City, Hyogo Prefecture, Chairman and President: Shin Ashida, hereinafter referred to as JCR Pharmaceuticals) to utilize EME's unique humanized VHH screening platform (a combination of the "PharmaLogical Library" (*1) and cDNA display technology (*2) for efficiently acquiring VHH antibodies suitable for drug discovery, hereinafter referred to as the platform) for drug discovery related to next-generation VHH antibodies (*3).

Inquiry about this news
Contact Us OnlineMore Details & Registration
Details & Registration
Related Documents
Related Links
EME has signed a joint research and development agreement with JCR Pharma Co., Ltd. (Headquarters: Ashiya City, Hyogo Prefecture, Chairman and President: Shin Ashida, hereinafter referred to as JCR Pharma) to utilize EME's unique humanized VHH screening platform for drug discovery related to next-generation antibody VHH.